Severity
Low
FDA Drug recall · Reported January 27, 2016
Super-Potent Drug: Out of Specification Assay test results were reported for stability samples.
Morton Grove Pharmaceuticals, Inc. recalled Lindane Lotion, USP 1%, For External use Only, Rx Only, 2 fl oz (60 mL) bottle, MGP, NDC … - a low-severity action.
Lindane Lotion, USP 1%, For External use Only, Rx Only, 2 fl oz (60 mL) bottle, MGP, NDC … was recalled by Morton Grove Pharmaceuticals, Inc. in January 27, 2016. Reason: Super-Potent Drug: Out of Specification Assay test results were reported for stability samples.. Check the official notice for the remedy. Verify recall #D-0571-2016 with the FDA Drug before acting.
The recall
Morton Grove Pharmaceuticals, Inc. issued this low-severity FDA Drug recall-Super-Potent Drug: Out of Specification Assay test results were reported for stability samples..
Sourced from official FDA Drug enforcement records. Verify recall #D-0571-2016 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0571-2016) was formally reported on January 27, 2016, with the manufacturer initiating the action on December 15, 2015. It is classified under Low severity (Class III), with a current status of Terminated. Morton Grove Pharmaceuticals, Inc. is listed as the recalling firm, operating out of Morton Grove, IL. Federal records list the affected scope as 39,187 bottles.
The documented reason for this recall is: Super-Potent Drug: Out of Specification Assay test results were reported for stability samples. Distribution data in the federal record shows the product reached: Nationwide and Puerto Rico. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
39,187 bottles
Related Recalls
6
5 from same agency
Lindane Lotion, USP 1%, For External use Only, Rx Only, 2 fl oz (60 mL) bottle, MGP, NDC 60432-833-60
Super-Potent Drug: Out of Specification Assay test results were reported for stability samples.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-0571-2016 |
| Date reported | January 27, 2016 |
| Date initiated | December 15, 2015 |
| Recalling firm | Morton Grove Pharmaceuticals, Inc. |
| Firm location | Morton Grove, IL |
| Affected scope | 39,187 bottles |
| Distribution | Nationwide and Puerto Rico |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported January 27, 2016. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.